Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target $638.88 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$634.44 -4.44 (-0.69%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 27 Analyst RatingsSell0Hold10Buy17 Based on 27 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 10 have given a hold rating, 15 have given a buy rating, and 2 have given a strong buy rating for REGN. Consensus Price Target $792.6524.07% Upside According to the 27 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $792.65. The highest price target for REGN is $995.00, while the lowest price target for REGN is $255.00. The average price target represents a forecasted upside of 24.07% from the current price of $638.88. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for REGN and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. REGN Analyst Ratings Over TimeTypeCurrent Forecast5/25/25 to 5/25/261 Month Ago4/25/25 to 4/25/263 Months Ago2/24/25 to 2/24/261 Year Ago5/25/24 to 5/25/25Strong Buy2 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)2 Strong Buy rating(s)Buy15 Buy rating(s)17 Buy rating(s)14 Buy rating(s)18 Buy rating(s)Hold10 Hold rating(s)9 Hold rating(s)9 Hold rating(s)2 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)Consensus Price Target$792.65$818.13$793.81$884.79Forecasted Upside24.07% Upside8.86% Upside2.80% Upside50.39% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy REGN Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History REGN Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Regeneron Pharmaceuticals Stock vs. The CompetitionTypeRegeneron PharmaceuticalsMedical CompaniesBroader MarketConsensus Rating Score 2.70 2.30 2.52Consensus RatingModerate BuyHoldModerate BuyPredicted Upside24.07% Upside1,718.96% Upside15.09% UpsideNews Sentiment RatingNeutral NewsSee Recent REGN NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails5/19/2026 Canaccord Genuity Group4 of 5 starsJohn Newman3 of 5 starsLower TargetBuy$1,057.00 ➝ $875.00+39.73%5/18/2026 BMO Capital Markets4 of 5 starsEvan David3 of 5 starsLower TargetOutperform$900.00 ➝ $730.00+16.09%5/18/2026 Truist Financial3 of 5 starsGregory RenzaNot RatedLower TargetBuy$796.00 ➝ $778.00+24.55%5/18/2026 JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingChris SchottSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$950.00 ➝ $850.00+35.88%5/18/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian AbrahamsSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetSector Perform$762.00 ➝ $707.00+13.43%5/18/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMohit BansalSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetEqual Weight$800.00 ➝ $700.00+12.30%5/18/2026 Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBiren AminSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$875.00 ➝ $855.00+37.17%5/18/2026 CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingGeoff MeachamSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Neutral$900.00 ➝ $700.00+0.25%5/18/2026 Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAndrew BerensSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$792.00 ➝ $641.00-8.20%5/1/2026 GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingYatin SunejaSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$975.00 ➝ $995.00+41.25%ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.See the 5 stocks to avoid4/30/2026 BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingEliana MerleSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOverweight$923.00 ➝ $917.00+29.94%4/23/2026 TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTyler VanSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$880.00 ➝ $960.00+26.14%4/23/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCarter GouldSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOverweight$800.00+5.03%4/10/2026 Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew HarrisonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetEqual Weight$769.00 ➝ $796.00+6.60%4/8/2026 Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingWilliam PickeringSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetOutperform$925.00 ➝ $921.00+20.76%3/27/2026 Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Reiterated RatingHold (C)2/6/2026 Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating DowngradeStrong-Buy ➝ Hold2/2/2026 OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingMatthew BieglerSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingReiterated RatingOutperform$750.00 ➝ $865.00+14.68%1/22/2026 EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingCory KasimovSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetOutperform$750.00 ➝ $875.00+15.64%1/7/2026 Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTim AndersonSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingUpgradeUnderperform ➝ Buy$627.00 ➝ $860.00+10.75%11/24/2025 HSBCSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy11/24/2025 ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLouise ChenSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetSector Perform$650.00 ➝ $770.00-0.01%11/7/2025 UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingTrung HuynhSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetNeutral$595.00 ➝ $660.00+2.02%9/2/2025 Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeModerate Buy8/27/2025 Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingAkash TewariSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingBoost TargetBuy$813.00 ➝ $831.00+41.41%8/14/2025 Rothschild & Co RedburnSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating UpgradeStrong-Buy6/30/2025 ArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingJasper HellwegSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingDowngradeBuy ➝ Hold4/30/2025 The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSalveen RichterSubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetBuy$917.00 ➝ $804.00+36.25%4/25/2025 Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBrian SkorneySubscribe to MarketBeat All Access for the analyst's recommendation accuracy ratingLower TargetNeutral$759.00 ➝ $652.00+8.71%2/4/2025 Bernstein BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Lower Target$1,070.00 ➝ $1,000.00+44.18%11/15/2024 Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy rating Initiated CoverageOutperform$1,150.00+46.96%Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:39 AM ET. Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, May 22, 2026. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com. Regeneron Pharmaceuticals Bull Case Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: The current stock price is around $720, which may present a buying opportunity for investors looking for growth in the biotechnology sector. Regeneron Pharmaceuticals, Inc. has a strong pipeline of biologic therapies, indicating potential for future revenue growth as new products are developed and commercialized. The company recently announced a strategic collaboration with Parabilis Medicines, which could lead to significant milestone payments and royalties, enhancing its financial outlook. With institutional investors holding over 83% of the company's stock, there is a strong level of confidence from large financial entities, which can be a positive indicator for retail investors. The company has a low dividend payout ratio of 9.16%, suggesting that it retains a significant portion of its earnings for reinvestment, which could drive future growth. Regeneron Pharmaceuticals Bear Case Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: Recent setbacks in clinical trials, such as the phase 3 melanoma trial for fianlimab missing its main goal, have weakened confidence in some of the company's high-profile pipeline assets. Analyst downgrades have occurred following the trial results, with several brokerages lowering their price targets, indicating a more cautious outlook on the stock's performance. Despite a strong institutional presence, insider selling activity has been noted, which may raise concerns about the confidence of company executives in the stock's future performance. The current dividend yield is relatively low at 0.6%, which may not attract income-focused investors looking for higher returns from dividends. Market sentiment has been mixed, with some analysts issuing hold ratings, suggesting that the stock may not be a strong buy at this time. REGN Forecast - Frequently Asked Questions What is Regeneron Pharmaceuticals' forecast for 2026? According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $792.65, with a high forecast of $995.00 and a low forecast of $255.00. Should I buy or sell Regeneron Pharmaceuticals stock right now? 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 10 hold ratings, 15 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" REGN shares. Does Regeneron Pharmaceuticals's stock price have much upside? According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 24.07% based on their 12-month stock forecasts. Has Regeneron Pharmaceuticals been downgraded by Wall Street analysts recently? Over the previous 90 days, Regeneron Pharmaceuticals's stock had 1 downgrade by analysts. What analysts cover Regeneron Pharmaceuticals? Regeneron Pharmaceuticals has been rated by research analysts at Barclays, BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Guggenheim, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, Truist Financial, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Regeneron Pharmaceuticals more than its competitors? Analysts like Regeneron Pharmaceuticals more than other "medical" companies. The consensus rating for Regeneron Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how REGN compares to other companies. Stock Forecasts and Research Tools Related Companies AMGN Stock Forecast GILD Stock Forecast MRNA Stock Forecast NTLA Stock Forecast VIR Stock Forecast VRTX Stock Forecast ABBV Stock Forecast LLY Stock Forecast MRK Stock Forecast PFE Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Regeneron Pharmaceuticals RecommendationsCanaccord Genuity GroupWells Fargo & CompanyTruist FinancialRoyal Bank Of CanadaCitigroupBMO Capital MarketsJPMorgan Chase & Co.Piper SandlerLeerink PartnersWall Street ZenGuggenheimBarclaysCantor FitzgeraldTD CowenMorgan Stanley This page (NASDAQ:REGN) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
